The board of directors of Dawnrays Pharmaceutical Holdings Ltd. announced that in order to comply with the forthcoming amendments to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited which will be effective on 1 April 2012, Ms. Li Kei Ling ceased to be the chairman of the remuneration committee of the company but remains as a member of the Remuneration Committee. Mr. Pan Xue Tian, an independent non-executive director of the company, has been appointed as the chairman of the Remuneration Committee with effect from 28 March 2012.